FDA adcomm votes against Otsuka's Rexulti-Zoloft combo for PTSD

The FDA’s Psychopharmacologic Drugs Advisory Committee on Friday voted 10-1 against the combination of Otsuka’s Rexulti and the antidepressant Zoloft, raising concerns about a failed Phase 3 clinical trial and the fact that both parts ...